<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635373</url>
  </required_header>
  <id_info>
    <org_study_id>13-093</org_study_id>
    <nct_id>NCT02635373</nct_id>
  </id_info>
  <brief_title>European Calciphylaxis Registry Network</brief_title>
  <acronym>EuCalNet</acronym>
  <official_title>European Calciphylaxis Registry Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, registry, prospective, non-interventional collection of CUA patient data.
      Patient treatment is carried out within clinical routine, at the discretion of the physicians
      and according to existing treatment guidelines. Participating physicians will not be subject
      to any instructions with regard to the diagnosis and therapy of their patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calcific uremic arteriolopathy (CUA, calciphylaxis) is a rare disease (ORPHA280062) with
      dramatically high mortality characterized clinically by the occurrence of painful
      debilitating cutaneous lesions and ulcerations. Median survival time is about 1.5 years. Many
      uncertainties still exist about risk factors and optimal therapy. CUA mainly occurs in
      patients with severe renal insufficiency or ESRD.

      The aim of the present initiative is to establish an international (European) observational
      registry for CUA patients. This registry will help to reach a critical mass of CUA patients,
      will allow novel insights into pathophysiology, and will help establishing systematically an
      overview upon risk factors and long-term outcome of CUA patients. The design of the
      international registry is supposed to adopt the structure of the presently running
      nation-wide German calciphylaxis registry.

      The investigators plan to initiate a registry in which treating physicians can provide data
      upon demographics, clinical picture, comorbidities, medical treatments and laboratory data at
      the time of diagnosis and serial follow-up time points. In addition investigators will
      build-up a biobank for full blood, serum and plasma samples as well as tissue samples.

      The registry will allow investigations regarding potential subgroups of patients (proximal
      versus distal forms of CUA), geno-phenotype correlations, description of international
      state-of-the-art treatment, and identification of preventive tools, risk factors and
      biomarkers for estimation of prognosis.

      Furthermore, the registry will be the nidus for further scientific exchange between experts
      and clinicians on the field of uremic vascular calcification.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Prognosis of patients with calciphylaxis (survival time)</measure>
    <time_frame>5 years</time_frame>
    <description>Survival time is defined as 1) time between diagnosis of calciphylaxis and death (or end of follow-up) or 2) - in case time of diagnosis is not recorded - time between registry recording and death (or end of follow-up). Analysis of survival time is done using the Kaplan-Meier survival analysis and Kaplan-Meier plot. With a Cox hazard model, we will try to identify additional factors influencing survival time. Hereby it is possible to take into consideration interaction between the parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnosis of calciphylaxis</measure>
    <time_frame>5 years</time_frame>
    <description>An internet based multilingual registry in which treating physicians can provide patients` data (online questionnaire) upon: demographics, the clinical picture including photo documentation and pain scale (VAS) reporting, comorbidities, medical treatments including dialysis and operations, wound management and laboratory data (serum-creatinine, , BUN, ionized / total calcium, serum phosphorus, PTH, alkaline, phosphatase, calcidiol, albumin, CRP, HbA1c, cholesterol, ferritin, hemoglobin, leukocyte count). The international registry will allow a more rapid identification of patients with calciphylaxis than on a national basis alone, will help establish diagnostic algorithms, and will increase the awareness of the disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors</measure>
    <time_frame>5 years</time_frame>
    <description>More detailed identification of risk factors: the registry will allow investigations regarding potential subgroups of patients (proximal versus distal forms of CUA), geno-phenotype correlations, description of international state-of-the-art treatment, and identification of preventive tools, risk factors and biomarkers for estimation of prognosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors influencing prognosis of patients with calciphylaxis</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation of the collected data from the time point of diagnosis and serial follow-up time points and further scientific exchange between experts and clinicians on the field of uremic vascular calcification will allow identification of subgroups of patients with potentially distinct pattern of risk factors, clinical picture and prognosis, and establishing factors influencing prognosis of patients with calciphylaxis and to develop novel and/or individualized treatment strategies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Novel therapeutic options</measure>
    <time_frame>5 years</time_frame>
    <description>By increasing the reported cases towards a critical threshold in Europe enabling the performance of RCTs comparing available or upcoming therapeutic options in CUA pts.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Calcific Uremic Arteriolopathy (CUA)</condition>
  <condition>Calciphylaxis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diagnosed CUA
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed CUA according to the judgement of locally treating physicians, who have the
             option to ask for external diagnostic advice from the country-specific
             sub-investigators

          -  Male or female aged &gt; 18 years

          -  Written informed consent prior to study participation

          -  The subject is not mentally or legally incapacitated

        Exclusion Criteria:

        • The subject is not able to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vincent Brandenburg, MD, Prof.</last_name>
    <phone>+49 (0)241/80</phone>
    <phone_ext>36072</phone_ext>
    <email>calciphylaxis@ukaachen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medicine, Division of Cardiology, Pulmonary Diseases and Vascular Medicine at the University Hospital, RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Verena Deserno, M.Sc.</last_name>
      <phone>+49 241 80</phone>
      <phone_ext>80092</phone_ext>
      <email>vdeserno@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Vincent Brandenburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Weenig RH. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol. 2008 Mar;58(3):458-71. doi: 10.1016/j.jaad.2007.12.006. Epub 2008 Jan 18. Review.</citation>
    <PMID>18206262</PMID>
  </reference>
  <reference>
    <citation>Brandenburg VM, Cozzolino M, Ketteler M. Calciphylaxis: a still unmet challenge. J Nephrol. 2011 Mar-Apr;24(2):142-8. Review.</citation>
    <PMID>21337312</PMID>
  </reference>
  <reference>
    <citation>Meissner M, Gille J, Kaufmann R. Calciphylaxis: no therapeutic concepts for a poorly understood syndrome? J Dtsch Dermatol Ges. 2006 Dec;4(12):1037-44. Review. English, German.</citation>
    <PMID>17176411</PMID>
  </reference>
  <reference>
    <citation>Hafner J, Keusch G, Wahl C, Sauter B, Hürlimann A, von Weizsäcker F, Krayenbühl M, Biedermann K, Brunner U, Helfenstein U. Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol. 1995 Dec;33(6):954-62. Review.</citation>
    <PMID>7490365</PMID>
  </reference>
  <reference>
    <citation>Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001 Jul;60(1):324-32.</citation>
    <PMID>11422768</PMID>
  </reference>
  <reference>
    <citation>Janigan DT, Hirsch DJ, Klassen GA, MacDonald AS. Calcified subcutaneous arterioles with infarcts of the subcutis and skin (&quot;calciphylaxis&quot;) in chronic renal failure. Am J Kidney Dis. 2000 Apr;35(4):588-97. Review.</citation>
    <PMID>10739777</PMID>
  </reference>
  <reference>
    <citation>Kramann R, Brandenburg VM, Schurgers LJ, Ketteler M, Westphal S, Leisten I, Bovi M, Jahnen-Dechent W, Knüchel R, Floege J, Schneider RK. Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrol Dial Transplant. 2013 Apr;28(4):856-68. doi: 10.1093/ndt/gfs466. Epub 2012 Dec 6.</citation>
    <PMID>23223222</PMID>
  </reference>
  <reference>
    <citation>Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002 Jun;61(6):2210-7.</citation>
    <PMID>12028462</PMID>
  </reference>
  <reference>
    <citation>Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007 Apr;56(4):569-79. Epub 2006 Dec 1.</citation>
    <PMID>17141359</PMID>
  </reference>
  <reference>
    <citation>Brandenburg VM, Floege J, Ketteler M. Kalzifizierende urämische Arteriolopathie. Der Nephrologe 2009; 4(1):65-66</citation>
  </reference>
  <reference>
    <citation>Krueger T, Westenfeld R, Schurgers L, Brandenburg V. Coagulation meets calcification: the vitamin K system. Int J Artif Organs. 2009 Feb;32(2):67-74. Review.</citation>
    <PMID>19363777</PMID>
  </reference>
  <reference>
    <citation>Jahnen-Dechent W, Schäfer C, Ketteler M, McKee MD. Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification. J Mol Med (Berl). 2008 Apr;86(4):379-89. Epub 2007 Dec 15. Review.</citation>
    <PMID>18080808</PMID>
  </reference>
  <reference>
    <citation>Cranenburg EC, Vermeer C, Koos R, Boumans ML, Hackeng TM, Bouwman FG, Kwaijtaal M, Brandenburg VM, Ketteler M, Schurgers LJ. The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res. 2008;45(5):427-36. doi: 10.1159/000124863. Epub 2008 Apr 10.</citation>
    <PMID>18401181</PMID>
  </reference>
  <reference>
    <citation>Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003 Aug;112(3):357-66.</citation>
    <PMID>12897203</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2015</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calciphylaxis</keyword>
  <keyword>Rare disease (ORPHA280062)</keyword>
  <keyword>Renal insufficiency</keyword>
  <keyword>ESRD</keyword>
  <keyword>Calcification</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Vascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calciphylaxis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

